0
0
Industry
Geography
Report Type
Themes
Price
Publication date
Published Date
  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – EyeGate Pharmaceuticals Inc

    Kiora Pharmaceuticals Inc (Kiora), formerly EyeGate Pharmaceuticals Inc, is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company's pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company which focuses on the development of drugs for the treatment of light related severe skin disorders. The company’s lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other products under development includes CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – NeuroBo Pharmaceuticals Inc

    NeuroBo Pharmaceuticals Inc (NeuroBo), formerly Gemphire Therapeutics Inc, is a clinical stage biopharmaceutical company that focuses on developing novel therapeutics for neurodegenerative and cardiometabolic diseases. The company has pipeline product candidates include ANA001, an oral niclosamide formulation developed for moderate coronavirus disease (COVID-19 which is phase 2 clinical trials. Gemcabene for the treatment of homozygous familial hypercholesterolemia (HoFH) and hypertriglyceridemia (SHTG) which is a serious medical condition that increases the risk of life-threatening cardiovascular diseases; NB-01 for painful diabetic neuropathy...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Acadia Pharmaceuticals Inc

    Acadia Pharmaceuticals Inc (Acadia) discovers, develops, and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company’s marketed product Nuplazid (pimavanserin) is an FDA-approved drug for the treatment of Parkinson’s disease psychosis. It's pipeline includes pimavanserin for the treatment of various indications which include Schizophrenia, Major Depressive Disorder (MDD), dementia-related psychosis (DRP), and trofinetide for the treatment of Rett Syndrome. The company markets its product in the US. It has operational presence in Denmark, Switzerland,...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Aerie Pharmaceuticals Inc

    Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. The company’s product comprise rhopressa, a once-daily eye drop that is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Kala Pharmaceuticals Inc

    Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company. It offers nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s AMPPLIFY technology, treats the medical needs for the front of the eye, and NCEs, targeted to address front and back of the eye diseases. Its pipeline products includes EYSUVIS (loteprednol etabonate ophthalmic suspension), is used for the treatment of short-term (up to two weeks) treatment of the signs and symptoms of dry...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Ampio Pharmaceuticals Inc

    Ampio Pharmaceuticals Inc (Ampio) operates as a biopharmaceutical company. The company discovers and develops novel therapeutic candidates for inflammatory conditions. It provides treatments for inflammatory conditions including osteoarthritis of the knee and osteoarthritis related to other joints such as the hip, shoulder, ankle and hand. The company also offers intra-articular injection treatment for severe OAK, intravenous and inhaled treatment for hospitalized severe COVID-19 patients and inhalation treatment for patients. It operates a manufacturing facility in the US. Ampio is headquartered...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Zynerba Pharmaceuticals Inc

    Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002. Its ZYN002 is a synthetic CBD, a non- cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN002 is administered as a transdermal gel to children and adolescents with autism spectrum disorder. The company’s pipeline candidates target various indications which include...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Infinity Pharmaceuticals Inc

    Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company which discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. The company is evaluating IPI-549 as a monotherapy and in a combination therapy in various clinical trials for the treatment of various indications such advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple...

  • Innovation Ranking

    New
    $1,995 | March 2024
    Innovation Ranking
    New

    Innovation Ranking – Hepion Pharmaceuticals Inc

    Hepion Pharmaceuticals Inc (Hepion) formerly known as ContraVir Pharmaceuticals Inc, is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its potency and selective index against HBV. Its products are used for the treatment of chronic hepatitis B and shingles. Hepion serves atients and healthcare professionals by developing differentiated therapeutic products. The company operates in the US. Hepion...

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.